Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer

Kazunori Honda, Bishal Gyawali, Masashi Ando, +11

Journal of Global Oncology

Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer

Keiji Sugiyama, Yukiya Narita, Seiichiro Mitani, +8

Anticancer Research

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study

Kazunori Honda, Bishal Gyawali, Masashi Ando, +8

ecancermedicalscience

FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis

Toshiki Masuishi, Shigenori Kadowaki, Mayumi Kondo, +10

Anticancer Research

Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study

Takashi Kurosaki, Seiichiro Mitani, Kaoru Tanaka, +12

Anti-Cancer Drugs

Cetuximab-containing RegimensNeoadjuvant TherapySquamous Cell CarcinomaMedicineImmunology +13

Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis

Seiichiro Mitani, Shigenori Kadowaki, Isao Oze, +11

Cancer Medicine

Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer

Takashi Kurosaki, Hisato Kawakami, Seiichiro Mitani, +8

In Vivo

Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer

Kyoko Kato, Yukiya Narita, Seiichiro Mitani, +8

Anticancer Research

Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer

Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, +14

European Journal of Cancer

MedicineImmunologyPathologyBronchial NeoplasmImmune Checkpoint Inhibitor +6

The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study

Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, +17

Frontiers in Immunology